Bristol Myers Squibb Company $BMY Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 8.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,540,268 shares of the biopharmaceutical company’s stock after purchasing an additional 448,265 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Bristol Myers Squibb were worth $319,230,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Bayban acquired a new position in Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the fourth quarter valued at $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

BMY stock opened at $64.71 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market cap of $132.18 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The business has a fifty day moving average of $59.75 and a two-hundred day moving average of $59.06.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Analyst Ratings Changes

Several brokerages have recently issued reports on BMY. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating for the company. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. boosted their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.